ALXO 1.21 (-1.63%)
US00166B1052BiotechnologyBiotechnology

ALX Oncology Holdings (ALXO) Stock Highlights

1.21 | -1.63%
2024-11-21 06:01:55
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a dont eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Statistics

Range Today
1.21 1.25
Volume Today 579.9K
Range 1 Year
1.19 17.83
Volume 1 Year 193.78M
Range 3 Year
1.19 39.62
Volume 3 Year 411.74M
Range 10 Year
1.19 117.45
Volume 10 Year 488.33M

Highlights

Market Capitalization 76.48M (small)
Floating Shares 27.1M
Current Price 1.21
Price To Earnings -0.43
Price To Book 0.56
Earnings Per Share -3.64
Payout Ratio 0%

Performance

Latest -1.63%
1 Month -18.24%
3 Months -53.46%
6 Months -91.35%
1 Year -87.24%
3 Years -96.85%
5 Years -96.77%
10 Years -96.77%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.